European Commission Approves COSENTYX

European Commission Approves COSENTYX as First and Only IL-17A Inhibitor for Hidradenitis Suppurativa

European Commission Approves COSENTYX as First and Only IL-17A Inhibitor for Hidradenitis Suppurativa

SG Tylor

Source: Novartis On June 1, 2023, Novartis announced that the European Commission (EC) has granted approval for the use of ...